In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor

By E. Perzborn, J. Straßburger, A. Wilmen, J. Pohlmann, S. Roehrig, Schlemmer Kh, Alexander T. Straub. Journal of Thrombosis and Haemostasis, 2005

619 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/fff715baa620bfac1440856b95b6842a20ab2594

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. D. Remick

Citations in the corpus

• The Pathogenesis of Sepsis (2011, background): “(85) describe the anti–Factor Xa activity of BAY 59–7934 (rivaroxaban), which is from a class of oxazolidinone derivatives, identified during high-throughput screening, that are competitive inhibitors of Factor Xa directed against the enzyme’s active site; they have a relatively short half-life but ”
• Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects (2005, background): “BAY 59-7939 is a direct FXa inhibitor and is more than 10,000-fold more selective for FXa than for other related serine proteases [ 1 ].”